Search…

Kangchen Pharmaceutical (603590.SH): The KC1086 project has obtained FDA approval to conduct clinical trials.

24/12/2025

Smart Finance and Economics APP News, Kangchen Pharmaceuticals (603590.SH) announced that recently, the company has received a "Notice to Continue Clinical Research" issued by the Food and Drug Administration (FDA) of the United States. The company's application for clinical trials of KC1086 tablets has officially been granted FDA approval.

Latest

2 m ago

Netflix: TRC Capital proposes to acquire 1.25 million shares of Netflix at $91 per share. Shareholders are urged to reject TRC's mini-tender offer.

2 m ago

Huakang Clean: Consortium wins pre-bid for 157 million yuan hospital special department procurement project.

2 m ago

According to the AI Express of Every Greater China, Huayuan Securities released a research report on December 24th giving a "buy" rating to Kejia Precision Machinery (301338.SZ). The main reasons for the rating include: 1) being a global leader in solder paste printing equipment, opening a new chapter in AI; 2) AI demand driving the high-end demand for solder paste printing equipment, with the company's main business seeing an increase in both quantity and price; 3) the company's new products are achieving success, raising the growth ceiling further. (Daily Economic News)

3 m ago

Sdic (300806.SZ) subsidiary Taicang Sdic intends to introduce investor Industrial Bank Gold Investment Co., Ltd. to receive a capital increase of 250 million yuan.

3 m ago

Jiaxian shares: The phase I technological transformation and capacity expansion project of Yingtemei is expected to be completed by the end of the first quarter of 2026.

See all latest